The $350M raise provides substantial cash runway for pipeline advancement, but the dilutive offering at a premium to recent trading levels signals aggressive capital needs. Watch for the final prospectus supplement for exact share count and any insider participation. The overallotment exercise will determine total dilution.
Price Chart
Executive Summary
Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares at $85.00/share, with an underwriter option for an additional ~$52.5M. The proceeds will fund pipeline programs in gastroenterology, rheumatology, and dermatology, including advancing SPY072 into late-stage development for hidradenitis suppurativa. The offering is dilutive to existing shareholders and follows a preliminary 424B5 filed earlier today.
Key Financial Metrics
Key Facts
- Priced 4,117,648 shares at $85.00 per share for gross proceeds of ~$350.0 million
- Underwriters have a 30-day option to purchase up to an additional ~$52.5 million of shares
- Offering expected to close on or about October 7, 2026
- Proceeds to fund preclinical studies, clinical trials, manufacturing, Phase 3 readiness, and SPY072 for hidradenitis suppurativa
- Joint book-running managers: Jefferies, TD Cowen, Leerink Partners, Stifel; passive bookrunner: LifeSci Capital
- Offering conducted under effective S-3ASR shelf (File No. 333-297063) filed June 26, 2026
Financial Impact
~$350M gross proceeds from 4.1M new shares; ~$52.5M additional if overallotment exercised; dilution of approximately 5-7% based on pre-offering share count (not stated explicitly)
Risk Factors
- Dilution of existing shareholders from 4.1M new shares plus potential overallotment
- Execution risk in advancing multiple programs across three therapeutic areas
- Clinical-stage company with no approved products; pipeline failure could impair value
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $92.73 (+7.95%) |
Oct 9, 2026 16d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $92.73 (+7.95%) |
Oct 7, 2026 19d ago | 8-K | $80.85 | awaiting T+20 | — | $92.73 (−14.69%) |
Oct 6, 2026 19d ago | 424B5 | $80.85 | awaiting T+20 | — | $92.73 (−14.69%) |
Oct 5, 2026 20d ago | Press Release | $80.11 | awaiting T+20 | — | $92.73 (−15.75%) |
Oct 5, 2026 20d ago | 424B5 | $80.11 | awaiting T+20 | — | $92.73 (−15.75%) |
Oct 5, 2026 20d ago | Press Release | $80.11 | awaiting T+20 | — | $92.73 (−15.75%) |
Oct 2, 2026 23d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $92.73 (−0.01%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $92.73 (−4.21%) |
Aug 10, 2026 10w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $92.73 (+9.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers